How is the Ph-like signature being incorporated into ALL therapy?

Luke Maese, Sarah K. Tasian, Elizabeth A. Raetz

Research output: Contribution to journalReview articlepeer-review

12 Scopus citations

Abstract

Philadelphia chromosome-like acute lymphoblastic leukemia (Ph-like ALL) is a recently identified high risk disease subtype characterized by a gene expression profile similar to that observed in Philadelphia chromosome-positive (Ph-positive) ALL, but without an underlying BCR-ABL1 translocation. Adults and children with Ph-like ALL harbor a diversity of alterations that all lead to activated kinase signaling. Outcomes for patients with Ph-like ALL are poor, which has prompted investigation into the role of tyrosine kinase inhibitor (TKI)-based therapies for this disease. Several clinical trials are now ongoing that include screening for the Ph-like signature and treatment of patients with Ph-like ALL with TKI therapy. This review examines how testing for Ph-like ALL is being incorporated into clinical trials.

Original languageEnglish
Pages (from-to)222-228
Number of pages7
JournalBest Practice and Research in Clinical Haematology
Volume30
Issue number3
DOIs
StatePublished - Sep 2017
Externally publishedYes

Keywords

  • Acute lymphoblastic leukemia
  • Dasatinib
  • Imatinib
  • Janus kinase inhibitor
  • Philadelphia chromosome-like
  • Ruxolitinib
  • tyrosine kinase inhibitor

Fingerprint

Dive into the research topics of 'How is the Ph-like signature being incorporated into ALL therapy?'. Together they form a unique fingerprint.

Cite this